Morgan Stanley analyst Sean Laaman raised the firm’s price target on Exelixis (EXEL) to $49 from $48 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis price target raised to $51 from $49 at Truist
- Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
- Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
- Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley